# Natural Products in the Metabolic and Endocrine Modulation of Polycystic Ovary Syndrome: Current Perspectives

**Authors:** Siqi Liu, Rui Wang, Weili Yu, Chuanjing Shi, Xi Wang, Aifen Liu, Lei Zhang

PMC · DOI: 10.3390/nu18060964 · Nutrients · 2026-03-18

## TL;DR

This review explores how natural products can help manage polycystic ovary syndrome by improving metabolism, hormones, and inflammation.

## Contribution

The paper systematically summarizes how natural products modulate multiple pathways in PCOS treatment.

## Key findings

- Natural products improve insulin sensitivity and reduce oxidative stress in PCOS.
- They modulate the hypothalamic–pituitary–gonadal axis to reduce hyperandrogenemia.
- Emerging evidence suggests gut microbiota and epigenetic regulation as new therapeutic avenues.

## Abstract

Polycystic ovary syndrome (PCOS) is a prevalent endocrine and metabolic disorder, primarily characterized by reproductive dysfunction, insulin resistance (IR), and long-term metabolic complications. Current first-line pharmacological treatments, including oral contraceptives, anti-androgens, and insulin sensitizers, can alleviate clinical symptoms but often fail to fully address the underlying pathophysiology, and their long-term use is frequently limited by adverse effects. Natural products, owing to their multi-target regulatory properties and favorable safety profiles, have emerged a promising adjuvant therapeutic strategy. This review systematically summarizes how natural products exert beneficial effects through mechanisms such as improving metabolic homeostasis by enhancing insulin sensitivity and mitigating oxidative stress and chronic inflammation; restoring endocrine balance by modulating the hypothalamic–pituitary–gonadal axis to reduce hyperandrogenemia and promote ovulation; and utilizing emerging pathways including regulating gut microbiota homeostasis and epigenetic modifications as a novel avenue for PCOS drug development. Preclinical and clinical evidence collectively indicates that these agents hold significant translational potential to ameliorate metabolic disturbances and improve reproductive outcomes, providing a scientific foundation for future integrated intervention strategies in PCOS.

## Linked entities

- **Diseases:** Polycystic ovary syndrome (MONDO:0008487)

## Full-text entities

- **Genes:** INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}
- **Diseases:** inflammation (MESH:D007249), endocrine and metabolic disorder (MESH:D004700), metabolic disturbances (MESH:D024821), PCOS (MESH:D011085), chronic (MESH:D002908), IR (MESH:D007333), reproductive dysfunction (MESH:D060737)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13029731/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13029731/full.md

## References

271 references — full list in the complete paper: https://tomesphere.com/paper/PMC13029731/full.md

---
Source: https://tomesphere.com/paper/PMC13029731